Schiavi & Co LLC Invests $385,000 in Agilent Technologies, Inc. (NYSE:A)

Schiavi & Co LLC purchased a new position in Agilent Technologies, Inc. (NYSE:A - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 2,866 shares of the medical research company's stock, valued at approximately $385,000. Agilent Technologies comprises about 0.2% of Schiavi & Co LLC's investment portfolio, making the stock its 18th biggest holding.

Other hedge funds also recently bought and sold shares of the company. CKW Financial Group raised its position in Agilent Technologies by 114.9% in the 4th quarter. CKW Financial Group now owns 187 shares of the medical research company's stock worth $25,000 after buying an additional 100 shares during the last quarter. Global X Japan Co. Ltd. lifted its position in Agilent Technologies by 161.1% during the fourth quarter. Global X Japan Co. Ltd. now owns 188 shares of the medical research company's stock valued at $25,000 after purchasing an additional 116 shares during the period. Redwood Park Advisors LLC bought a new stake in Agilent Technologies in the 4th quarter worth approximately $27,000. Lee Danner & Bass Inc. bought a new position in shares of Agilent Technologies during the 4th quarter valued at $29,000. Finally, Hanson & Doremus Investment Management boosted its stake in shares of Agilent Technologies by 66.5% in the 4th quarter. Hanson & Doremus Investment Management now owns 263 shares of the medical research company's stock worth $35,000 after buying an additional 105 shares during the last quarter.

Agilent Technologies Price Performance

Shares of Agilent Technologies stock traded down $0.30 during trading hours on Wednesday, reaching $102.82. The company's stock had a trading volume of 591,465 shares, compared to its average volume of 2,069,553. The stock has a market cap of $29.31 billion, a P/E ratio of 23.64, a P/E/G ratio of 2.96 and a beta of 1.19. Agilent Technologies, Inc. has a one year low of $96.43 and a one year high of $155.35. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.20 and a quick ratio of 1.66. The firm has a 50 day moving average price of $122.01 and a 200-day moving average price of $133.33.

Remove Ads

Agilent Technologies (NYSE:A - Get Free Report) last released its earnings results on Wednesday, February 26th. The medical research company reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.27 by $0.04. The firm had revenue of $1.68 billion for the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a return on equity of 25.56% and a net margin of 19.27%. On average, analysts predict that Agilent Technologies, Inc. will post 5.55 EPS for the current year.

Agilent Technologies Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 23rd. Shareholders of record on Tuesday, April 1st will be given a dividend of $0.248 per share. The ex-dividend date of this dividend is Tuesday, April 1st. This represents a $0.99 annualized dividend and a dividend yield of 0.96%. Agilent Technologies's dividend payout ratio (DPR) is presently 22.76%.

Insider Activity

In other news, CEO Padraig Mcdonnell sold 1,911 shares of the firm's stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $150.00, for a total transaction of $286,650.00. Following the transaction, the chief executive officer now directly owns 39,652 shares of the company's stock, valued at approximately $5,947,800. This trade represents a 4.60 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Daniel K. Podolsky sold 1,819 shares of the firm's stock in a transaction on Monday, March 31st. The stock was sold at an average price of $116.46, for a total value of $211,840.74. Following the transaction, the director now owns 35,737 shares in the company, valued at $4,161,931.02. The trade was a 4.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 5,638 shares of company stock valued at $731,229.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Citigroup raised their target price on Agilent Technologies to $165.00 and gave the stock a "buy" rating in a research report on Thursday, December 19th. TD Cowen upped their price objective on Agilent Technologies to $135.00 and gave the stock a "buy" rating in a research note on Thursday, April 10th. StockNews.com raised Agilent Technologies from a "hold" rating to a "buy" rating in a report on Tuesday, December 24th. Barclays decreased their price objective on Agilent Technologies from $138.00 to $115.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 10th. Finally, Robert W. Baird lowered their price target on shares of Agilent Technologies from $161.00 to $159.00 and set an "outperform" rating on the stock in a report on Thursday, February 27th. Seven analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $146.25.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.